MedTrace Logo

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

NCT01012830 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2009-11-13

No results posted yet for this study

Summary

Use Huperzine-A, a herbal supplement normally used for treatment of Alzheimer's disease, to potentially improve cognitive dysfunction (memory problems) and functional capacity (ability to perform common daily tasks such as cooking, bathing, telephone, shopping) in people with schizophrenia.

Conditions

Interventions

DRUG

Huperzine A

Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.

Sponsors & Collaborators

  • American Legion of Iowa Foundation

    collaborator OTHER

  • VA Nebraska Western Iowa Health Care System

    lead FED

Principal Investigators

  • Prasad R Padala, MD, MS · VA Office of Research and Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-12-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01012830 on ClinicalTrials.gov